α-CGRP disrupts amylin fibrillization and regulates insulin secretion: implications on diabetes and migraine-Reference-Cited by-同舟云学术

α-CGRP disrupts amylin fibrillization and regulates insulin secretion: implications on diabetes and migraine

Published:2021 Issue:16 Volume:12 Page:5853-5864
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Gray Amber L. H.¹²³⁴^ORCID,Antevska Aleksandra¹²³⁴,Link Benjamin A.¹²³⁴,Bogin Bryan⁵⁶⁷⁴⁸,Burke Susan J.⁹¹⁰¹¹⁴,Dupuy Samuel D.¹²¹³¹⁴³⁴,Collier J. Jason¹⁵¹⁰¹¹⁴,Levine Zachary A.⁵⁶⁷⁴⁸,Karlstad Michael D.¹²¹³¹⁴³⁴,Do Thanh D.¹²³⁴^ORCID

Affiliation:

1. Department of Chemistry

2. University of Tennessee

3. Knoxville

4. USA

5. Department of Pathology

6. Yale School of Medicine

7. New Haven

8. Department of Molecular Biophysics & Biochemistry

9. Laboratory of Immunogenetics

10. Pennington Biomedical Research Center

11. Baton Rouge

12. Department of Surgery

13. Graduate School of Medicine

14. University of Tennessee Health Science Center

15. Laboratory of Islet Biology and Inflammation

Abstract

CGRP concentration is elevated in migraine conditions. The protective effect of migraine against type 2 diabetes is attributed to the ability of CGRP to remodel human amylin aggregation and to suppress the secretion of mouse insulin 2 (the orthologue of human insulin).

Funder

National Institutes of Health

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/SC/D1SC01167G

Reference97 articles.

1. Protein aggregation diseases: pathogenicity and therapeutic perspectives

2. Protein aggregation and neurodegenerative disease

3. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases